Clinical trial NCT03526900
Conditions: Non-small Cell Lung Cancer Stage IV
Sponsor: Spanish Lung Cancer Group
Start date: 2018-07-07; Completion date: 2022-09-15
Enrollment: 40 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
This is a multicenter, national, nonrandomized, phase II trial in subjects with nonsquamous NSCLC patients that have untreated asymptomatic BM. A pre-screening period using brain MRI for patients diagnosed with advanced non-squamous NSCLC EGFR/ALK wild type and ECOG PS 0-1 will be crucial to identify patients with asyntomatic BM. Forty patients will be recruited.

Detailed description:
Atezolizumab will be administered intravenously (iv) at a dose of 1200 mg over 60 minutes on day 1 of each cycle. The subsequent cycles of atezolizumab can be administered over 30 minutes, if there were no infusion-related toxicities. Pemetrexed will be administered at a dose of 500 mg/m2 iv over 15 minutes on day 1 of each cycle. In addition, folic acid, vitamin B12, and dexamethasone 4mg bid will be administered one day before and after pemetrexed treatment. Carboplatin will be administered at a dose with an area under the curve of 5 over 30 minutes on day 1 of each cycle approximately 30 minutes after the end of the pemetrexed infusion. After completing 4 to 6 cycles of carboplatin plus pemetrexed and atezolizumab, patients will continue with pemetrexed in combination with atezolizumab until unacceptable toxicity, disease progression, patient/physician decision or completion of 2 years of therapy.

Tumor measurements by CT scan (systemic response) and brain MRI (intracranial response) will be performed every 6 weeks until the 12th week and thereafter every 9 weeks until disease progression. In case of brain progression, rescue with brain radiotherapy should be considered. In case of exclusive brain progression, patients are allowed to receive brain radiotherapy (WBRT or SRS) and then continue with study therapy if the patients maintain clinical benefit and appropriate performance status (ECOG PS≤2).Immunotherapy should be started no later than 4 weeks after completing radiation therapy (brain radiotherapy 2 weeks + 4 weeks of recovery from potential acute toxicity). In case of systemic progression without brain progression, a novel line of systemic treatment should be considered. Patients experiencing systemic progression and/or brain progression will be followed and two post-progression visits will be performed at 30 and 90 days.

Response will be assessed independently in the brain and systemically: systemic response will be evaluated according to RECIST v1.1 and brain response according to the RANO response assessment criteria for BM (RANO-BM). Adverse events will be assessed throughout and assessed using the CTCAE version 4.03. EORTC quality of life questionnaire EORTC C30 and the submodules QLQ-LC13 and BN20 will be assessed in the ITT population at baseline, cycle 5 (week 12),cycle 9 (week 24), at end of study treatment (30 and 90 days) and/or at disease progression. Periodic evaluations of the trial data will be conducted by an independent DMC to ensure subject safety and to evaluate the efficacy at the interim analyses. Neurocognitive assessment including the standardized neuropsychological tests: Hopkins Verbal Learning Test (HVLT), Trail Making Test (TMT), Rey-Osterrieth complex figure test (ROCF) and Controlled Oral Word Association Test (COWA) will be assessed at baseline cycle 5 (week 12),cycle 9 (week 24), at end of study treatment (30 and 90 days) and/or at disease progression.

Arms: arm 1: Induction phase: atezolizumab will be given intravenously (iv) at a dose of 1200 mg for 60 minutes on day 1 of each cycle. Subsequent atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity. Pemetrexed will be administered at a dose of 500 mg/m2 IV for 15 minutes on day 1 of each cycle. In addition, folic acid, vitamin B12, and dexamethasone 4 mg will be given the day before and the day after treatment with pemetrexed. Carboplatin will be given at a dose with an area under the 5 curve for 30 minutes on day 1 of each cycle, approximately 30 minutes after the pemetrexed infusion is complete. After completing 4 to 6 cycles of Carboplatino plus pemetrexed and atezolizumab, patients will continue with pemetrexed in combination with atezolizumab (maintenance phase) until they have an unacceptable toxicity, progression of the disease, decision of the patient/physician or have Completed 2 years of treatment.
Interventions: intervention 1: Atezolizumab
Intervention descriptions: intervention 1: * Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2
* Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2.

Protocol documents:
Prot_SAP_000.pdf: 
    
 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
CONFIDENTIAL 
 
 
 
 
 Official Title: 
 
 
 
NCT Number: 
 
 
 
Document Dates: Summary of Protocol Amendment Version 3.1:  
10 December 2020 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
2 
 
 
 
 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
3 
 
 
Contacts 
 
Trial Chair (Principal 
Investigator) 
Dr. Marta Simó  
Avenida Meridiana 358, 6ªplanta 
08027 Barcelona 
Tel. 93 430 20 06 
Fax. 93 419 17 68 
Email: 
pharmacovigilance.slcg@gecp.org 
 
Email: tbaz@gecp.org
Avenida Meridiana 358, 6ªplanta 
08027 Barcelona 
Tel. 93 430 20 06 
Fax. 93 419 17 68 
 
 
Anna Hernández 
Avenida Meridiana 358, 6ªplanta 
08027 Barcelona 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
4 
 
 
 
 
 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
5 
 
 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
6 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
7 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
8 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
9 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
10 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
11 
 
 
 
 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
12 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
13 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
14 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
15 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
16 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
17 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
18 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
19 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
20 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
21 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
22 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
23 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
24 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
25 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
26 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
27 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
28 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
29 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
30 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
31 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
32 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
33 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
34 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
35 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
36 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
37 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
38 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
39 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
40 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
41 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
42 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
43 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
44 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
45 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
46 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
47 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
48 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
49 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
50 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
51 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
52 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
53 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
54 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
55 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
56 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
57 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
58 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
59 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
60 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
61 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
62 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
63 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
64 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
65 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
66 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
67 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
68 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
69 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
70 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
71 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
72 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
73 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
74 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
75 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
76 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
77 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
78 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
79 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
80 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
81 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
82 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
83 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
84 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
85 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
CONFIDENTIAL 


 
 
 
 
 
 
Appendix 1-Schedule of Activities (cont.) 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
87 
 
 


 
 
 
 
 
 
Appendix 1-Schedule of Activities (cont.) 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
88 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
CONFIDENTIAL 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
90 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
91 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
92 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
93 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
94 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
95 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
96 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
CONFIDENTIAL 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
98 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
99 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
100 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
101 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
102 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
103 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
104 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
105 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
106 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
107 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
108 
 
 


 
ATEZO-BRAIN_GECP 17/05_v.3.1_10_December_2020 
109